# TempraMed (CSE:VIVI)

> TempraMed is dedicated to creating innovative solutions that protect patients from damaged medications, particularly those that are temperature sensitive.

## About

TempraMed is dedicated to creating innovative solutions that protect patients from damaged medications, particularly those that are temperature sensitive. Their technology ensures that medications remain safe and effective from the point of production to the patient, addressing the critical 'last mile' of pharmaceutical management.

## Key facts

- **Cash position:** not discovered
- **Shares outstanding:** 77,669,893
- **Fully diluted shares:** 111,495,927
- **Warrants:** 15,230,596
- **Options:** 8,444,856
- **Mineral resource:** not discovered
- **Projects:** not discovered
- **Leadership:** Ilan Cohen (Executive Chairman, Serial entrepreneur and Former Director of the Israeli Prime minister's office.), Ron Nagar (Founder and CEO, Medical device serial entrepreneur and inventor. Co-Founder InsuLine Medical and Glucon.), David Ben Naim (Finance Manager, An experienced finance manager of development stage private and public companies.), Daniel Salomon (US Strategic Accounts Advisor, Ex Teva Executive 17 years at Teva. Served as Head of Sales and Marketing for Teva USA institutional business unit.), Gabriel Bitton Ph.D (VP R&D, Medical device development, Simulations, Diabetes and drug delivery expert co-founder InsuLine Medical.), Elina Nagar (Co-Founder and COO, Decades of experience in operations and systems for medical devices and Dietician.), Brenda Zeitlin (VP Marketing, More than 25 years of experience in bringing new products to market.), Angelica Khachaturova (VP Business Development, Global Business Development, Strategy, Sales Growth and Marketing, Digital Health and Medical Devices expert.), Gal Cohen (E-commerce Manager, Implementing long-term online marketing strategies for eCommerce brands.), Prof. Andreas Pfutzner M.D. (Medical Director, Managing Director and Founder of PFÜTZNER Science & Health Institute GmbH/ Germany.), Roger Goldman (Board Member, Senior Executive, Public Speaker and Advisor for corporate boards and management teams.), Ran Enoch (Board of Directors, Digital Entrepreneur Executive & Advisor in global online businesses.), Jason Albanese (Board of Directors, Serial entrepreneur Digital Marketing specialist. Strategic planning and business development specialist.), Jennifer L. Carter MD (Board of Directors, Serial entrepreneur and Healthcare Executive. Managing Director at Sandbox Healthcare & The Blue Venture Fund.), Susan Alpert MD, PhD (Chief Regulatory Advisor, Former Director of Device Evaluation at the FDA, Senior VP Global Regulatory affairs at Medtronic.), Brian Hopkins JD (Special Counsel, US IP attorney with over 25 years of experience in intellectual property.), Prof. William V. Tamborlane (Scientific & Medical Advisor, Honored Professor and Chief of Pediatric Endocrinology at Yale School of Medicine.), Dr. Diana Isaacs (Medical Advisor, Endocrine Clinical Pharmacist. 2020 ADCES Diabetes Care & Education Specialist of the Year.), Peter Feinstein M.D (Medical Advisory board, Orthopedic surgeon. Extensive experience in investment and business strategies for interests in and outside the field of medicine.)

_Verified data last updated: 2026-05-15_

## Investor FAQ

### [Latest news?](https://chat.orbiton.app/tempramed/faq/latest-news)

Not disclosed in available filings.

## Live AI chat

- https://chat.orbiton.app/tempramed/chat
- Investor website: https://tempramed.com/?srsltid=AfmBOop4o8KUeXRXEPQYpDKLl7t-3xVFTxM3xtgC5ELLySDbA0QksRoW